| Code | CSB-RA896537MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to TRX-518, targeting TNFRSF18 (tumor necrosis factor receptor superfamily member 18), also known as GITR (glucocorticoid-induced TNFR-related protein). TNFRSF18 is a co-stimulatory receptor predominantly expressed on regulatory T cells (Tregs) and activated effector T cells, playing a critical role in modulating immune responses. Upon engagement with its ligand GITRL, TNFRSF18 enhances T cell proliferation, cytokine production, and effector function while potentially attenuating Treg-mediated immunosuppression. This dual mechanism makes TNFRSF18 a compelling target in cancer immunotherapy, autoimmune diseases, and transplantation research.
TRX-518 is a humanized IgG1 monoclonal antibody designed to activate TNFRSF18 signaling, promoting anti-tumor immunity by enhancing effector T cell responses and modulating the suppressive tumor microenvironment. This biosimilar antibody serves as a valuable research tool for investigating TNFRSF18-mediated immune regulation, exploring checkpoint modulation strategies, and evaluating combination immunotherapy approaches in preclinical models.
There are currently no reviews for this product.